List of Myrbetriq Granules drug patents

Myrbetriq Granules is owned by Apgdi.

Myrbetriq Granules contains Mirabegron.

Myrbetriq Granules has a total of 8 drug patents out of which 2 drug patents have expired.

Expired drug patents of Myrbetriq Granules are:

  • US6346532*PED
  • US6346532

Myrbetriq Granules was authorised for market use on 25 March, 2021.

Myrbetriq Granules is available in for suspension, extended release;oral dosage forms.

Myrbetriq Granules can be used as treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older by administration of an extended-release suspension formulation of mirabegron.

The generics of Myrbetriq Granules are possible to be released after 01 October, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6346532 APGDI Amide derivatives or salts thereof
Mar, 2022

(10 months ago)

US7342117 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(9 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6346532

(Pediatric)

APGDI Amide derivatives or salts thereof
Sep, 2022

(4 months ago)

US7982049 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(9 months from now)

US7982049

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(1 year, 3 months from now)

US7342117

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(1 year, 3 months from now)

US10058536 APGDI Pharmaceutical composition containing mirabegron
Mar, 2036

(13 years from now)

US10058536

(Pediatric)

APGDI Pharmaceutical composition containing mirabegron
Oct, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 25, 2024
Pediatric Exclusivity (PED) Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

Market Authorisation Date: 25 March, 2021

Treatment: Treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older by administration of an extended-release suspension formulation of mirabegron

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in